Patent application number | Description | Published |
20080269192 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds - Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X | 10-30-2008 |
20100136554 | SUPPORTED REAGENTS, METHODS, AND DEVICES - Methods of providing at least one reagent for use in a device for processing sample material, delivering at least one reagent to a device for processing sample material, and adding at least one reagent to at least one of the steps in a process for detecting or assaying a nucleic acid; a support film coated with a dry reagent layer; and a device for processing sample material having a support film coated with a dry reagent layer contained within at least one chamber of the device are disclosed. | 06-03-2010 |
20110020947 | CHEMICAL COMPONENT AND PROCESSING DEVICE ASSEMBLY - A substantially dimensionally-stable chemical component is assembled with a sample processing device via a computer-controlled apparatus. In one embodiment, surface mount technology is used to assemble the chemical component with the processing device. The chemical component may include, for example, chemicals used for sample preparation or detection, such as a reagent. In different embodiments, the chemical component may be a tablet, microtablet, lyophilized pellet, bead, film, and so forth. In some embodiments, the chemical components are stored within a carrier that packages a plurality of chemical components. The carrier may define a plurality of pockets, where each pocket defines a discrete space for holding at least one chemical component. In some embodiments, a robotic arm aligns with a pocket in order to locate and remove a chemical component from the carrier and transfer the chemical component to a chamber of a processing device. | 01-27-2011 |
20110207725 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS - Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X | 08-25-2011 |
20110293654 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS - Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R | 12-01-2011 |
20120232057 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS - Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X | 09-13-2012 |
20140370046 | BETA-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS - Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell. | 12-18-2014 |
20150125451 | COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY - This disclosure describes, in one aspect, a composition that includes a β-glucan component and an antibody component that specifically binds to the β-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to β-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of β-glucan and administering to the subject a composition that comprises a β-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody. | 05-07-2015 |
20150125461 | BETA-GLUCAN IMMUNOTHERAPEUTIC METHODS - This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder. | 05-07-2015 |